Radiomics Profiling Identifies the Incremental Value of MRI Features beyond Key Molecular Biomarkers for the Risk Stratification of High-Grade Gliomas
Table 1
Patient characteristics in the training set and external validation set.
Characteristic
Training set (N = 134)
Ex-validation set (N = 107)
value
Age (year)
54 (43–62)
53.93 ± 15.54
0.212
Gender
0.216
Female
52 (38.8%)
50 (46.7%)
Male
82 (61.2%)
57 (53.3%)
Histology
0.008
Non-GBM
68 (50.7%)
36 (33.6%)
GBM
66 (49.3%)
71 (66.4%)
IDH genotype
0.006
Wild type
76(56.7%)
79 (73.8%)
Mutation
58(43.3%)
28 (26.2%)
MGMT promoter
0.986
Unmethylation
54 (40.3%)
43 (40.2%)
Methylation
80 (59.7%)
64 (59.8%)
Overall survival (day)
466.5 (253.75–927.25)
508 (254v958)
0.816
Note. GBM: glioblastoma; IDH: isocitrate dehydrogenase; MGMT: O6-methylguanine methyltransferase. The training set was from our institution, and the external validation set was from the TCGA/TCIA dataset. A value <0.05 was considered a significant difference.
